These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9236054)

  • 21. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.
    Riedl K; Riedl R; von Gabain A; Nagy E; Lingnau K
    Vaccine; 2008 Jun; 26(27-28):3461-8. PubMed ID: 18495302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice.
    Higgins DA; Carlson JR; Van Nest G
    Vaccine; 1996 Apr; 14(6):478-84. PubMed ID: 8782343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.
    Caproni E; Tritto E; Cortese M; Muzzi A; Mosca F; Monaci E; Baudner B; Seubert A; De Gregorio E
    J Immunol; 2012 Apr; 188(7):3088-98. PubMed ID: 22351935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Vaccine; 2006 Nov; 24(44-46):6629-31. PubMed ID: 16901593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
    Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
    J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
    Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
    J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
    Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
    Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
    J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
    Puig Barberà J; González Vidal D
    Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine.
    Segura-Velázquez R; Pérez-Torres A; Rosas G; Toledo A; Restelli M; Acosta E; Corral R; Rosetti F; Fragoso G; Grinstein S; Sciutto E
    Vaccine; 2006 Feb; 24(8):1073-80. PubMed ID: 16202486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
    Leroux-Roels I; Van der Wielen M; Kafeja F; Vandermeulen C; Lazarus R; Snape MD; John T; Carre C; Nougarede N; Pepin S; Leroux-Roels G; Hoppenbrouwers K; Pollard AJ; Van Damme P
    Vaccine; 2009 Nov; 27(49):6918-25. PubMed ID: 19761837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.